Sanofi snaps up acne vaccine developer Origimm Bio
pharmaphorum
DECEMBER 1, 2021
Sanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. Oral isotretinoin can also be effective but is associated with serious side effects so is generally a last-line option.
Let's personalize your content